Biohaven Ltd
BHVN15.110USD
+1.750+13.10%
收盘 07/17, 16:00（美东）报价延迟15分钟
1.54B总市值
亏损市盈率 TTM
关于 Biohaven Ltd 公司
Biohaven Ltd. 是一家临床阶段的生物制药公司。该公司专注于发现、开发和商业化关键治疗领域的治疗方法，包括免疫学、神经科学和肿瘤学。其临床和临床前项目包括用于治疗癫痫和情绪障碍的 Kv7 离子通道调节；用于治疗免疫疾病的细胞外蛋白质降解；用于治疗偏头痛和神经性疼痛的瞬时受体电位黑素 3 (TRPM3) 拮抗剂；用于治疗神经炎症疾病的酪氨酸激酶 2/Janus 激酶 1 (TYK2/JAK1) 抑制；用于治疗强迫症 (OCD) 和脊髓小脑共济失调 (SCA) 的谷氨酸调节；用于治疗神经肌肉和代谢疾病（包括脊髓性肌萎缩症 (SMA) 和肥胖症）的肌生长抑制素抑制；以及用于治疗癌症的抗体募集、双特异性分子和抗体药物偶联物 (ADC)。 Troriluzole 是一种新化学实体 (NCE)，是活性代谢物利鲁唑的三肽前体药物。
公司简介
公司代码BHVN
公司名称Biohaven Ltd
上市日期Sep 23, 2022
成立日期2022
CEODr. Vlad Coric, M.D.
员工数量256
证券类型Ordinary Share
年结日Sep 23
公司地址215 Church Street
城市NEW HAVEN
上市交易所NYSE Consolidated
国家United States of America
邮编06510
电话12034040410
网址https://www.biohaven.com/
公司代码BHVN
上市日期Sep 23, 2022
成立日期2022
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月14日 周三
更新时间: 5月14日 周三
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
37.06%
Investment Advisor
28.02%
Hedge Fund
18.28%
Individual Investor
11.53%
Private Equity
2.88%
Research Firm
2.07%
Sovereign Wealth Fund
0.88%
Bank and Trust
0.64%
Venture Capital
0.51%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
560
104.96M
102.79%
-7.46M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.81M
4.71%
+385.00K
+8.69%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
RP Management, LLC
2.94M
2.88%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
iShares Neuroscience and Healthcare ETF
2.32%
Roundhill GLP-1 & Weight Loss ETF
1.24%
Simplify Health Care ETF
1.16%
Global X Guru Index ETF
1.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Tema Neuroscience and Mental Health ETF
0.56%
SPDR S&P Biotech ETF
0.45%
WisdomTree BioRevolution Fund
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Main Thematic Innovation ETF
0.23%
查看更多
iShares Neuroscience and Healthcare ETF
占比2.32%
Roundhill GLP-1 & Weight Loss ETF
占比1.24%
Simplify Health Care ETF
占比1.16%
Global X Guru Index ETF
占比1.15%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
Tema Neuroscience and Mental Health ETF
占比0.56%
SPDR S&P Biotech ETF
占比0.45%
WisdomTree BioRevolution Fund
占比0.3%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.26%
Main Thematic Innovation ETF
占比0.23%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
